The Bowel Cancer Screening Programme Expert Board: an analysis of activity during 2017-2020.


Journal

Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136

Informations de publication

Date de publication:
Apr 2022
Historique:
revised: 05 11 2021
received: 10 09 2021
accepted: 11 11 2021
pubmed: 14 11 2021
medline: 31 3 2022
entrez: 13 11 2021
Statut: ppublish

Résumé

The inception of the National Health Service Bowel Cancer Screening Programme in England in 2006 highlighted the fact that the differential diagnosis between the presence of epithelial misplacement and adenocarcinoma occurring in colorectal adenomas is problematic. The pathology Expert Board (EB) was created to facilitate the review of difficult cases by a panel of three experienced gastrointestinal pathologists. This article describes a review of the work of the EB over a 4-year period (2017-2020). Four hundred and thirty polyps were referred to the EB from 193 pathologists and 76 hospitals during this time. The EB diagnosis was benign for 67%, malignant for 28%, and equivocal for 2% (with no consensus in the remainder). The most common diagnosis change made by the EB was from malignant to benign-made in 50% of polyps referred with an initially malignant diagnosis. The level of agreement between the individual EB members was 'good' (kappa score of 0.619) but that between the EB and the referring diagnosis was 'poor' (kappa score of 0.149). Data from one EB member indicated that the presence of lamina propria, features of torsion and cytological similarity between the superficial and deep glands were predictors of a benign diagnosis, whereas the presence of irregular neoplastic glands, a desmoplastic reaction and lymphovascular invasion were commonly observed features in polyps with a malignant diagnosis. Diagnostic agreement between EB members is better than that between the EB and referring pathologists. There was a consistent trend for the EB to change diagnoses from malignant to benign.

Identifiants

pubmed: 34773294
doi: 10.1111/his.14597
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

782-789

Informations de copyright

© 2021 John Wiley & Sons Ltd.

Références

Loughrey MB, Quirke P, Shepherd NA. Standards and datasets for reporting cancers: dataset for colorectal cancer histopathology reports. Royal College of Pathologists, September 2018. Available at: https://www.rcpath.org/uploads/assets/c8b61ba0-ae3f-43f1-85ffd3ab9f17cfe6/G049-Dataset-for-histopathological-reporting-of-colorectal-cancer.pdf (accessed 19 August 2021).
Bowel cancer screening: pathology guidance on reporting lesions . Available at: www.gov.uk/government/publications/bowel-cancer-screening-reporting-lesions (accessed 15 August 2021).
Turner JK, Williams GT, Morgan M, Wright M, Dolwani S. Interobserver agreement in the reporting of colorectal polyp pathology among bowel cancer screening pathologists in Wales. Histopathology 2013; 62; 916-924.
Loughrey MB, Shepherd NA. The pathology of bowel cancer screening. Histopathology 2015; 66; 66-67.
Shepherd NA, Griggs RKL. Bowel cancer screening-generated diagnostic conundrum of the century: pseudoinvasion in sigmoid colonic polyps. Mod. Pathol. 2015; 28; S88-S94.
Griggs RKL, Novelli MR, Warren BF, Williams GT, Quirke P, Shepherd NA. Challenging diagnostic issues in adenomatous polyps with epithelial misplacement in bowel cancer screening: 5 years’ experience of the Bowel Cancer Screening Programme Expert Board. Histopathology 2017; 70; 466-472.
McHugh ML. Interrater reliability: the kappa statistic. Biochem. Med. 2012; 22; 276-282.
de Jonge L, Worthington J, van Wifferen F et al. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study. Lancet Gastroenterol. Hepatol. 2021; 6; 304-314.
Dinmohamed AG, Cellamare M, Visser O et al. The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands. J. Hematol. Oncol. 2020; 13; 147.
Lieberman D, Moravec M, Holub J, Michaels L, Eisen G. Polyp size and advanced histology in patients undergoing colonoscopy screening: implications for CT colonography. Gastroenterology 2008; 135; 1100-1105.

Auteurs

Adrian C Bateman (AC)

Department of Cellular Pathology, University Hospitals Southampton NHS Foundation Trust, Southampton, UK.

Octavia R Kurn (OR)

Department of Cellular Pathology, University Hospitals Southampton NHS Foundation Trust, Southampton, UK.

Marco R Novelli (MR)

Department of Histopathology, University College Hospital, London, UK.

Manuel Rodriguez-Justo (M)

Department of Histopathology, University College Hospital, London, UK.

Neil A Shepherd (NA)

Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Cheltenham, UK.

Newton A C S Wong (NACS)

Department of Cellular Pathology, Southmead Hospital, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH